OpenAI Launches GPT-Rosalind for Biomedical Research (heise.de)

• Model architecture optimized for genomics and molecular biology.
• Target discovery focus accelerates pharmaceutical pipelines.
• Restricted access outside the US market.

"OpenAI has introduced 'GPT-Rosalind', an AI model specifically tuned for biological data, genomics, and drug target discovery. The tool aims to streamline the identification of therapeutic pathways. Access is currently restricted to US-based corporate clients, highlighting potential challenges for European research institutions seeking parity in access to state-of-the-art bio-digital infrastructure."